Dementia
1,477
191
268
821
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Published Results
206 trials with published results (14%)
Research Maturity
821 completed trials (56% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.4%
50 terminated out of 1477 trials
94.3%
+7.8% vs benchmark
6%
89 trials in Phase 3/4
25%
206 of 821 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 821 completed trials
Clinical Trials (1477)
Music for Pain and Dementia
Managing the Needs of Care Home Residents With Dementia Through a Music Therapy Intervention
Combined Flow and Pressure Study of Craniospinal Dynamic
Physical Activity, Alzheimer's Disease and Cognition Relative to APOE Genotype
Italian Validation of the dNA Scale and Its Correlation With Neurocognitive Variables
100-Year Human Aging Study
Cerebral Amyloid Imaging Using Florbetapir (AV-45)
Educational Support Group Program for Bilingual and Spanish-speaking Carepartners and People With Progressive Aphasia
Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia
Efficacy of Caregiver Training Program in Enhancing Caregiver and Patient Outcomes
SUNAM Protocol for Managing BPSD
Alzheimer's Disease Neuroimaging Initiative 4
Validation and Reliability of the Turkish Version of the Montreal Cognitive Assessment-Basic (MoCA-B) in Individuals With Low Educational Level
Resilient Together for Dementia (RT-D)
CST+MST Intervention on People Living With Mild-to-moderate Dementia
Prediction and Prevention of Postoperative Mortality and Morbidity
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Innovative Cognitive Impairment Case Finding and Engagement for Diverse Participation in Alzheimer's Disease Care, Treatment, And Research
An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)